An FDA advisory committee voted 8-6 on Friday that the benefits of Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy outweigh its risks, lending their backing to accelerated approval of the treatment. In a day-long meeting, outside experts he…